|1.||Thorwarth, Daniela: 10 articles (10/2015 - 01/2005)|
|2.||Krohn, Kenneth A: 9 articles (03/2015 - 04/2004)|
|3.||Alber, Markus: 8 articles (10/2013 - 01/2005)|
|4.||Paulsen, Frank: 7 articles (06/2007 - 01/2005)|
|5.||Troost, Esther G C: 6 articles (10/2015 - 08/2006)|
|6.||Zips, Daniel: 6 articles (10/2015 - 10/2012)|
|7.||Kuge, Yuji: 6 articles (01/2015 - 05/2012)|
|8.||Tamaki, Nagara: 6 articles (01/2015 - 05/2012)|
|9.||Scott, Andrew M: 6 articles (05/2014 - 02/2002)|
|10.||Mönnich, David: 5 articles (10/2015 - 04/2011)|
10/01/2013 - "Both FMISO parameters are moderately effective in identifying hypoxia on the microscopic length scale (YI = 0.63 and 0.60). "
10/01/2015 - "Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia - a simulation study."
12/01/2014 - "Further study of double-baseline FMISO-PET/CT and hypoxia-directed RT dose escalation, particularly in patients at high risk for local recurrence, is warranted."
01/01/2013 - "The values of α0 estimated with NLSA from the time series of both [18 F]-FDG and [18 F]-FMISO increased significantly from normoxia to hypoxia in agreement with previous studies. "
09/01/2010 - "The role of PET in the visualization of the biological characteristics of the tumours: proliferation (FLT-PET), hypoxia (FMISO-PET) and angiogenesis/peptide expression (RGD-PET) should be investigated in future studies."
04/01/2015 - "The uptake and clearance of the individual [(18)F]FMISO antipodes were investigated using micro-PET/CT imaging performed on mice bearing FaDu tumors. "
01/01/2015 - "This study characterizes the hypoxic conditions of three tumor sublines (AT1, HI and H) of the Dunning R3327 prostate tumor model, which differ in histology, differentiation degree, volume doubling time and androgenic sensitivity, using dynamic Fluoromisonidazole ((18)F-FMISO)-Positron Emission Tomography/Computed Tomography (PET-CT) and histology. "
05/01/2014 - "Imaging studies using SK-RC-52 tumors in BALB/c nude mice have indicated that the tracer may have a higher pO₂ threshold than [¹⁸F]FMISO for uptake in hypoxic tumors. "
01/01/2013 - "The 2 positive studies on visual analysis of FMISO did not correspond to the largest tumors, the studies with the highest FMISO or FDG SUVmax. "
04/01/2009 - "MicroPET images and biodistribution studies showed that the accumulation of [(18)F]FMISO in the tumor is significantly higher than that in inflammatory lesion at 4 h post injection. "
07/01/2015 - "FMISO PET scan can predict early infarct growth in acute ischemic stroke patients with perfusion-diffusion mismatch in MRI."
07/01/2015 - "We hypothesized that FMISO PET might predict early infarct growth in acute ischemic stroke patients with perfusion-diffusion mismatch in magnetic resonance imaging (MRI). "
07/01/2015 - "(18)F-fluoromisonidazole (FMISO) Positron Emission Tomography (PET) Predicts Early Infarct Growth in Patients with Acute Ischemic Stroke."
04/01/2014 - "If confirmed in larger samples, this preliminary finding would have potential implications for the clinical application of FMISO PET in acute ischaemic stroke."
07/01/2006 - "Characterization of fluoromisonidazole binding in stroke."
01/01/2013 - "Ten patients with pancreatic carcinoma underwent FMISO and FDG PET scans. "
07/01/2005 - "C3H mammary carcinoma reached an FMISO PET ratio of 11 after 3.5 hours. "
01/01/2002 - "The aim of this study was to compare a non-invasive 18F-fluoromisonidazole ([18F]FMISO) PET assessment of tumour hypoxia with invasive Eppendorf pO2 measurements in 150-1,500 mm3 C3H mammary carcinomas transplanted on the back of CDF1 mice. "
07/01/2005 - "Less uptake of FMISO in SCCVII squamous-cell carcinoma than in C3H mammary carcinoma could be caused by scattered foci versus confluent areas of viable hypoxic tissue in the 2 tumors, respectively."
10/01/2008 - "Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts."
|5.||Head and Neck Neoplasms (Head and Neck Cancer)
01/01/2014 - "This study demonstrates a weak correlation between hypoxic volume measured by F-FMISO PET and expressions of HIF-1α and p53 in head and neck cancer."
10/01/2015 - "Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome."
05/21/2009 - "Each voxelized tissue's time activity curve (TAC) was simulated with typical values of kinetic parameters, as deduced from FMISO-PET data from nine head-and-neck cancer patients. "
06/01/2007 - "Ten head-and-neck cancer patients were examined with dynamic FMISO PET before RT with 70 Gy and after approximately 20 Gy. Two of these patients had two additional dynamic FMISO scans during treatment. "
12/01/2006 - "A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer."
|2.||Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
|7.||Deoxyglucose (2 Deoxy D glucose)
|9.||copper (II) diacetyl- di(N(4)- methylthiosemicarbazone)
|3.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)
|5.||Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)